9 Meters Biopharma, Inc. (NMTR)
Market Cap | 71.96M |
Revenue (ttm) | n/a |
Net Income (ttm) | -42.70M |
Shares Out | 272.58M |
EPS (ttm) | -0.17 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,972,762 |
Open | 0.265 |
Previous Close | 0.264 |
Day's Range | 0.254 - 0.272 |
52-Week Range | 0.197 - 1.460 |
Beta | 0.49 |
Analysts | Buy |
Price Target | 3.32 (+1,157.6%) |
Earnings Date | Aug 11, 2022 |
About NMTR
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short ... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for NMTR stock is "Buy." The 12-month stock price forecast is 3.32, which is an increase of 1,157.58% from the latest price.
News
9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced ...
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel Syndrome RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-s...
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
Phase 2 VIBRANT study identifies a dose and dosing interval with >25% improvement in the primary endpoint of 24-hour mean total stool output reduction over 6 weeks Vurolenatide was generally well tolera...
Why Are 9 Meters Biopharma Shares Plunging Today?
9 Meters Biopharma Inc (NASDAQ: NMTR) completed a pre-specified interim analysis for the Phase 3 study of larazotide for patients with celiac disease who continue to experience gastrointestinal symptoms...
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Tria...
Additional analyses to determine if a subgroup of patients and/or symptoms may have been responsive to treatment Company remains on track to deliver vurolenatide Phase 2 short bowel syndrome results by ...
9 Meters Biopharma to Participate in the 2022 BIO International Convention
RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...
9 Meters Biopharma to Exhibit at Digestive Disease Week 2022
RALEIGH, NC / ACCESSWIRE / May 19, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced ...
9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Us...
RALEIGH, NC / ACCESSWIRE / May 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced ...
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022
On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in June Cash balance as of March 31, 2022, of $37.2 million is expected to fund ...
9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology...
RALEIGH, NC / ACCESSWIRE / May 5, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced t...
9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 St...
RALEIGH, NC and SANTA ROSA, CA / ACCESSWIRE / April 20, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive...
9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious...
RALEIGH, NC / ACCESSWIRE / April 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announce...
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021
RALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today pr...
9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
RALEIGH, NC / ACCESSWIRE / March 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announce...
9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / March 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...
9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment fo...
RALEIGH, NC / ACCESSWIRE / March 2, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...
9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and...
RALEIGH, NC / ACCESSWIRE / February 28, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, annou...
9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome...
RALEIGH, NC / ACCESSWIRE / February 25, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, annou...
9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference
RALEIGH, NC / ACCESSWIRE / February 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announc...
9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
RALEIGH, NC / ACCESSWIRE / January 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announ...
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experience RALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Bioph...
9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
RALEIGH, NC / ACCESSWIRE / January 4, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive d...
9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor ...
RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studyi...
9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bo...
RALEIGH, NC / ACCESSWIRE / December 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive...
Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in 9 Meters Biopharma, Inc. (NMTR)
The heavy selling pressure might have exhausted for 9 Meters Biopharma, Inc. (NMTR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Str...